Allogeneic hemopoietic stem cell transplantation for patients with myelofibrosis / 中国实用内科杂志

Allogeneic hematopoietic stem cell transplantation(allo-HSCT) is the only therapy to cure myelofibrosis(MF) at present. This article gives a review on the following problems: who needs allo-SCT, how to choose allo-SCT in the era of ruxolitinib, the role of Ruxolitinib in the transplantation, whether allo-SCT can cure MF, and how to improve the effect of allo-SCT to guide the allo-SCT, in order for MF patients in clinical work.